(E)-4-Hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease

Free Radical Biology and Medicine

Volumn 25, Issue 2, 1998, Pages 169-174

  Selley, Michael L ^a,b  

^a CANBERRA HOSPITAL   (Australia)

^b Pan Australia Labs Pty Ltd   (Australia)

Author keywords

(E) 4 Hydroxy 2 nonenal; Free radical; Glutathione; Lipid peroxidation; N Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 HYDROXYNONENAL; ALPHA TOCOPHEROL; GLUTATHIONE;

ADULT; AGED; ANIMAL CELL; ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; GAS CHROMATOGRAPHY; HUMAN; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADULT; AGED; ALDEHYDES; ANIMALS; BRAIN STEM; CROSS-LINKING REAGENTS; DRUG ADMINISTRATION ROUTES; GLUTATHIONE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MIDDLE AGED; PARKINSON DISEASE; SUBSTANTIA NIGRA; TIME FACTORS; VITAMIN E;

EID: 0032527641     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(98)00021-5     Document Type: Article

References (44)

1. Jenner P., Olanow C. W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 47:1988;S161-S170.
2. Dexter D. T., Wells F. R., Lees A. J., Agid F., Agid Y., Jenner P., Marsden C. D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52:1989;1830-1836.
3. Gerlach M., Ben-Shachar D., Riederer P., Youdim M. B. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63:1994;793-807.
4. Mann V. M., Cooper J. M., Daniel S. E., Srai K., Jenner P., Marsden C. D., Schapira A. H. V. Complex I, iron and ferritin in Parkinson's disease substantia nigra. Ann. Neurol. 36:1994;876-881.
5. Perry T. L., Godin D. V., Hansen S. Parkinson's disease a disorder due to nigral glutathione deficiency? Neurosci. Lett. 33:1982;305-310.
6. Perry T. L., Yong V. W. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra. Neurosci. Lett. 67:1986;269-274.
7. Riederer P., Sofic E., Rausch W.-D., Schmidt B., Reynolds G. P., Jellinger K., Youdim M. B. H. Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains. J. Neurochem. 52:1989;515-520.
8. Saggu H., Cooksey J., Dexter D., Wells F. R., Lees A., Jenner P., Marsden C. D. A selective increase in particulate superoxide dismutase activity in Parkinsonian substantia nigra. J. Neurochem. 53:1989;692-698.
9. Langstone J. W., Ballard P. A., Tetrud J. W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
10. Ballard P. A., Tetrud J. W., Langston J. W. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) seven cases. Neurology. 35:1985;949-956.
11. Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobowitz D. M., Kopin I. J. A primate model of parkinsonism selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine . Proc. Natl. Acad. Sci. USA. 80:1983;4546-4550.
12. Heikkila R. E., Hess A., Duvoisin R. C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science. 224:1984;1451-1453.
13. Temlett J. A., Landsberg J. P., Watt F., Grime G. W. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey evidence from proton microprobe elemental microanalysis . J. Neurochem. 62:1994;134-146.
14. Ferraro T. N., Golden G. T., DeMattei M., Hare T. A., Fariello R. G. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse. Neuropharmacology. 25:1986;1071-1074.
15. Castagnoli G. U., Chiba K., Trevor A. J. Potential bioactivation pathways for the neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 36:1985;225-230.
16. Chiueh C. C., Wu R. M., Mohanakumar K. P., Sternberger L. M., Krishna G., Obata T., Murphy D. L. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann. N.Y. Acad. Sci. 738:1994;25-36.
17. Perry T. L., Yong V. W., Clavier R. M., Jones K., Wright J. M., Foulks J. G., Wall R. A. Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neuroscience. 60:1985;109-114.
18. Yong V. W., Perry T. L., Krisman A. A. Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment. Neurosci. Lett. 63:1986;56-60.
19. Dexter D. T., Carter C. J., Wells F. R., Javoy-Agid F., Agid Y., Lees A., Jenner P., Marsden C. D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52:1989;381-389.
20. Dexter D. T., Holley A. E., Flitter W. D., Slater T. F., Wells F. R., Daniel S., Lees A. J., Jenner P., Marsden C. D. Increased levels of lipid hydroperoxides in the Parkinsonian substantia nigra; an HPLC and ESR study. Mov. Disord. 9:1994;92-97.
21. Kilinc A., Yalien A. S., Taga Y., Emerk K. Increased erythrocyte susceptibility to lipid peroxidation in human Parkinson's disease. Neurosci. Lett. 87:1988;307-310.
22. Kalra J., Rajput A. H., Mantha S. V., Chaudhary A. K., Prasad K. Oxygen free radical producing activity of polymorphonuclear leukocytes in patients with Parkinson's disease. Mol. Cell Biochem. 12:1992;181-186.
23. Molina J. A., Jimenez-Jimenez F. J., Fernandez-Calle P. Serum lipid peroxides in patients with Parkinson's disease. Neurosci. Lett. 136:1992;137-140.
24. + toxicity by deprenyl (selegiline). Ann. N.Y. Acad. Sci. 738:1994;214-221.
25. Esterbauer H., Schaur R. J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11:1991;81-128.
26. Griffin D. S., Segall H. J. Genotoxicity and cytotoxicity of selected pyrrolidine alkaloids, a possible alkenal metabolite of the aldehydes and related alkenals. Toxic. Appl. Pharmacol. 86:1986;227-234.
27. 2-resistant cell lines. Do aldehyde by-products of lipid peroxidation contribute to oxidative stress? Biochem. J. 267:1990;453-459.
28. Kaneko T., Kaji K., Matsuo M. Cytotoxicities of a linoleic acid hydroperoxide and its related aliphatic aldehydes toward cultured human umbilical vein endothelial cells. Chem.-Biol. Interact. 67:1988;295-304.
29. Mark R. J., Lovell M. A., Markesbery W. R., Uchida K., Mattson M. P. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J. Neurochem. 68:1997;255-264.
30. Jürgens G., Lang J., Esterbauer E. Modification of human low density lipoprotein by the lipid peroxidation product 4-hydroxynonenal. Biochim. Biophys. Acta. 875:1986;103-114.
31. Uchida K., Stadtman E. R. Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc. Natl. Acad. Sci. USA. 89:1992;4544-4548.
32. Selley M. L. Determination of the lipid peroxidation product (E)-4-hydroxy-2-nonenal in clinical samples by gas chromatography-negative-ion chemical ionisation mass spectrometry of the O-pentaflurobenzyl oxime. J. Chromatogr. (Biomed. Appl.). 691:1997;263-268.
33. Perry T. L., Yong V. W., Jones K., Wall R. A., Clavier R. M., Foulks J. G., Wright J. M. Effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its metabolite N-methy-4-phenylpyridinium ion on dopaminergic nigrostriatal neurons in the mouse. Neurosci. Lett. 58:1985;321-326.
34. Strohmaier H., Hinghofer-Szalkay H., Schaur R. J. Detection of 4-hydroxynonenal (HNE) as a physiological component in human plasma. J. Lipid Med. Cell Sig. 11:1995;51-61.
35. Ishikawa T., Esterbauer H., Sies H. Role of cardiac glutathione transferase and of the glutathione S-conjugate export system in biotransformation of 4-hydroxynonenal in the heart. J. Biol. Chem. 261:1986;1576-1581.
36. Svensson K., Johansson A. M., Magnusson T., Carlsson A. (+)-AJ76 and (+)-UH-232 Central stimulants acting as preferential dopamine autoreceptor antagonists . Naunyn Schmiedebergs Arch. Pharmacol. 334:1986;234-245.
37. Ahiskog J. E., Uitti R. J., Low P. A., Tyce G. M., Nickander K. K., Petersen R. C., Kokmen E. No evidence for systemic oxidative stress in Parkinson's or Alzheimer's disease. Mov. Disord. 10:1995;566-573.
38. Selley M. L., Bartlett M. R., McGuiness J. A., Hapel A. J., Ardlie N. G., Lacey M. J. Quantitative determination of the lipid peroxidation product trans-4-hydroxy-2-nonenal in biological samples by high performance liquid chromatography and combined capillary column gas chromatography-negative-ion chemical ionisation mass spectrometry. J. Chromatogr. (Biomed Appl.). 488:1989;329-340.
39. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E. R. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. USA. 93:1996;2696-2701.
40. Hao R., Norgren R. B., Lau Y. S., Pfeiffer R. F. Cerebrospinal fluid of Parkinson's disease patients inhibits the growth and function of dopaminergic neurons in culture. Neurology. 45:1995;138-142.
41. Hartley D. P., Ruth J. A., Petersen D. R. The hepatocellular metabolism of 4-hydroxynonenal by alcohol dehydrogenase, aldehyde dehydrogenase and glutathione S-transferase Arch. Biochem. Biophys. 316:1995;197-205.
42. Esterbauer H., Zollner H., Scholz N. Reaction of glutathione with conjugated carbonyls. Z. Naturforsch. 30:1975;466-473.
43. Youdim M. B., Lavie L. Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease. Life Sci. 55:1994;2077-2082.
44. Kruman I., Bruce-Kellar A. J., Bredesen D., Waeg G., Mattson P. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J. Neurosci. 17:1997;5089-5100.